Lyell Immunopharma

Advancing Next Generation CAR-T Cell Therapies

Growth and Expansion in CAR-T: In October, Lyell announced the acquisition of ImmPACT Bio to expand its focus on next generation CAR-T development. This acquisition strengthened Lyell’s pipeline with a dual-targeting CD19/CD20 CAR T-cell product candidate, IMPT-314, in hematological malignancies. This is paired with Lyell’s existing differentiated CAR T-cell product candidate, LYL-119, in solid tumors. Lyell is committed to advancing all types of CAR T-cell therapies in cancer types with gaps in treatment.
Supported by the Data: Lyell ended 2024 with new Phase 1/2 data from the IMPT-314 in B-cell Lymphoma at the American Society of Hematology (ASH) annual meeting. Data show a 100% objective response rate within 28 days and a 73% complete response rate within three months of treatment.
Key Events in 2025:
- Progression of LYL-119 and IMPT-314 programs in solid tumors and hematological malignancies respectively.
  - LYL-119: Initial clinical data anticipated from Phase 1 trial in patients with ROR1‑positive solid tumors
  - IMPT-314: Initiate pivotal trial in third line relapsed/refractory large B-cell lymphoma in the third-line setting